Wuhan YZY Biopharma Co., Ltd. Class H(HK:2496)
HK$4.000.00 (0.00%)
HK:2496
Wuhan YZY Biopharma Co., Ltd. Class H Revenue
HK$4.00
At close:0.00 (0.00%)
Want to see HK:2496 full AI Analyst Report?
Wuhan YZY Biopharma Co., Ltd. Class H (2496) Revenue
1 Followers
Wuhan YZY Biopharma Co., Ltd. Class H Revenue
Wuhan YZY Biopharma Co., Ltd. Class H had a revenue of 32.69M in the quarter ending Jun 30, 2026, with 97.24%. This bring the company's revenue in the last twelve months to 89.68M, Increased 13.26%. In the fiscal year ending Dec 31, 2025, Wuhan YZY Biopharma Co., Ltd. Class H had annual revenue of 65.13M with -39.59% growth.
- Revenue (ttm)
- 89.68M
- Revenue Growth
- -55.22%
- P/S Ratio
- 16.08
- Revenue/Employee
- HKD 614,412
- Employees
- 106
- Market Cap
- HKD 1.05B
Revenue Chart
Wuhan YZY Biopharma Co., Ltd. Class H Revenue - Annual
Revenue History
| Fiscal End Date | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 65.13M | -42.69M | -39.59% |
| Dec 31, 2024 | 107.81M | 95.89M | 804.31% |
| Dec 31, 2023 | 11.92M | 9.65M | 423.59% |
| Dec 31, 2022 | 2.28M | -9.90M | -81.30% |
| Dec 31, 2021 | 12.18M | 12.18M | ― |
| Dec 31, 2020 | 0.00 | ― | ― |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.